Discovery of new pyridine heterocyclic hybrids; design, synthesis, dynamic simulations, and in vitro and in vivo breast cancer biological assays DOI Creative Commons

Menna M. Abdelshaheed,

Hussein I. El‐Subbagh, Mohamed A. Tantawy

et al.

RSC Advances, Journal Year: 2023, Volume and Issue: 13(23), P. 15689 - 15703

Published: Jan. 1, 2023

Pyridine is a nitrogen bearing heterocyclic scaffold that shows wide range of biological activities. The pyridine nucleus has become an interesting target for medicinal chemistry researchers worldwide. Several derivatives exhibited good anticancer effects against diverse cell lines. Therefore, to explore new entities, novel were designed and synthesized evaluated their abilities in vitro vivo. All the compounds three different human cancer lines (Huh-7, A549 MCF-7) via MTT assay. Most significant cytotoxic Compounds 3a, 3b, 5a 5b showed superior antiproliferative activities Taxol. Where, compound 3b IC50 values 6.54, 15.54 6.13 μM compared Taxol (6.68, 38.05, 12.32 μM) Huh-7, MCF-7, respectively. Also, tubulin polymerization assay was carried out. most potent could significantly inhibit with 15.6, 4.03, 6.06 12.61 μM, Compound highest inhibitory effect value 4.03 combretastatin (A-4) (1.64 μM). Molecular modeling studies confirmed made essential binding interactions reference which assisted prediction structure requirements detected activity. Finally, vivo breast cancer.

Language: Английский

Steatotic liver disease‐associated all‐cause/cause‐specific mortality in the United States DOI
Donghee Kim, Karn Wijarnpreecha, George Cholankeril

et al.

Alimentary Pharmacology & Therapeutics, Journal Year: 2024, Volume and Issue: 60(1), P. 33 - 42

Published: April 22, 2024

Recently, a panel of multi-society experts proposed steatotic liver disease (SLD) as an alternative terminology for metabolic dysfunction-associated fatty (MAFLD) or nonalcoholic (NAFLD).

Language: Английский

Citations

18
Metabolic dysfunction-associated steatotic liver disease in adults DOI
Daniel Q. Huang, Vincent Wai–Sun Wong, Mary E. Rinella

et al.

Nature Reviews Disease Primers, Journal Year: 2025, Volume and Issue: 11(1)

Published: March 6, 2025

Language: Английский

Citations

3
Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity DOI Creative Commons
Hong‐Kyu Kim, Sung‐Jin Bae, Min Jung Lee

et al.

Clinical and Molecular Hepatology, Journal Year: 2023, Volume and Issue: 29(4), P. 987 - 1001

Published: July 5, 2023

Background/Aims: To investigate whether non-alcoholic fatty liver disease (NAFLD) in individuals without generalized obesity is associated with visceral fat (VFO), sarcopenia, and/or myosteatosis.Methods: This cross-sectional analysis included 14,400 (7,470 men) who underwent abdominal computed tomography scans during routine health examinations. The total muscle area (TAMA) and skeletal (SMA) at the 3<sup>rd</sup> lumbar vertebral level were measured. SMA was divided into normal attenuation (NAMA) low area, NAMA/TAMA index calculated. VFO defined by to subcutaneous ratio, sarcopenia body mass index-adjusted SMA, myosteatosis index. NAFLD diagnosed ultrasonography.Results: Of individuals, 4,748 (33.0%) had NAFLD, prevalence of among non-obese 21.4%. In regression analysis, both (men: odds ratio [OR] 1.41, 95% confidence interval [CI] 1.19–1.67, P<0.001; women: OR=1.59, CI 1.40–1.90, P<0.001) OR=1.24, 1.02–1.50, P=0,028; OR=1.23, 1.04–1.46, P=0.017) significantly after considering for other various risk factors, whereas OR=3.97, 3.43–4.59 [adjusted sarcopenia], OR 3.98, 3.44–4.60 myosteatosis]; OR=5.42, 4.53–6.42 OR=5.33, 4.51–6.31 all strongly adjustment known factors.Conclusions: addition VFO, NAFLD.

Language: Английский

Citations

32
The synergistic impact of type 2 diabetes and MASLD on cardiovascular, liver, diabetes‐related and cancer outcomes DOI Creative Commons
David R. Riley, Theresa Hydes,

Gema Hernadez

et al.

Liver International, Journal Year: 2024, Volume and Issue: 44(10), P. 2538 - 2550

Published: July 1, 2024

We examined the impact of a co-diagnosis metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes (T2D) on patient outcomes.

Language: Английский

Citations

13
Liver cancer risk across metabolic dysfunction-associated steatotic liver disease and/or alcohol: a nationwide study DOI
Byungyoon Yun, Heejoo Park, Sang Hoon Ahn

et al.

The American Journal of Gastroenterology, Journal Year: 2024, Volume and Issue: unknown

Published: June 27, 2024

INTRODUCTION: New terminologies of metabolic dysfunction-associated steatotic liver disease (MASLD) have been developed. We assessed hepatocellular carcinoma (HCC) risk across MASLD and/or alcohol intake. METHODS: included participants aged 40–79 years receiving a national health checkup from 2009 to 2010 in the Republic Korea, classified as follows: non-MASLD, MASLD, with increased intake (MetALD; weekly 210–420 g for male and 140–350 female individuals), alcohol-associated (ALD; excessive ≥420 or ≥350 individuals). The primary outcome was HCC incidence. estimated using multivariable Cox proportional hazard models. RESULTS: Among 6,412,209 participants, proportions MetALD, ALD cases were 59.5%, 32.4%, 4.8%, 3.4%, respectively. During follow-up (median 13.3 years), 27,118 had newly developed HCC. Compared (adjusted ratio [aHR] 1.66, 95% confidence interval [CI] 1.62–1.71) MetALD (aHR 2.17, CI 2.08–2.27) 2.34, 2.24–2.45) stepwise manner. Furthermore, older non-cirrhosis subgroups more vulnerable detrimental effects intake, concerning risk. older, female, cirrhosis subgroups, poses similar risks ALD. DISCUSSION: manner, compared non-MASLD. For an effective prevention HCC, comprehensive approach should be required modify both dysfunction habit.

Language: Английский

Citations

10
The relationship between serum uric acid level and non-alcoholic fatty liver disease in northern China: a retrospective cohort study DOI Creative Commons
Qianjun He, Xinyue Liu, Guoyong Ding

et al.

BMC Public Health, Journal Year: 2025, Volume and Issue: 25(1)

Published: Feb. 21, 2025

Language: Английский

Citations

1
Association Between Handgrip Strength and Cardiovascular Disease Risk in MASLD: A Prospective Study From UK Biobank DOI Creative Commons
Tae Seop Lim, Sujin Kwon,

Sung A. Bae

et al.

Journal of Cachexia Sarcopenia and Muscle, Journal Year: 2025, Volume and Issue: 16(2)

Published: March 4, 2025

Language: Английский

Citations

1
Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study DOI Creative Commons
Yewan Park, Jooyi Jung, Seungbong Han

et al.

Alimentary Pharmacology & Therapeutics, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 20, 2024

Summary Background The new nomenclature of metabolic dysfunction‐associated steatotic liver disease (MASLD) substituting nonalcoholic fatty was proposed along with a category MASLD increased alcohol intake (MetALD). Aims We aimed to explore the cancer risk by and MetALD. Methods This nationwide cohort study included 3,596,709 participants who underwent health check‐up in 2011 South Korea. Steatotic (SLD) defined as index ≥30. Participants were categorized into four exclusive groups: MASLD, MetALD, other combination aetiology no SLD. subdistribution hazard ratio (SHR) calculated using Fine–Gray model after adjusting variables. Results During 33.9 million person‐years follow‐up, 285,845 (7.9%) developed cancers. Compared SLD, MetALD had an all cancer. Liver escalated from SLD (SHR, 1.16; 95% CI, 1.12–1.21), 2.06; 1.92–2.20) 8.16; 7.69–8.67). Gastrointestinal cancers including oesophagus, stomach, colorectal, biliary pancreas 1.13; 1.11–1.15), 1.17; 1.14–1.21) 1.09; 1.05–1.13). A modest increase lung hormone‐sensitive observed MASLD. Conclusions showed that are associated cancer, particularly gastrointestinal findings build evidence for clinical outcomes while highlighting importance managing properly

Language: Английский

Citations

7
From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials DOI Creative Commons
Ming‐Lun Yeh, Ming‐Lung Yu

Clinical and Molecular Hepatology, Journal Year: 2023, Volume and Issue: 29(4), P. 969 - 972

Published: Sept. 18, 2023

Language: Английский

Citations

13
Perspective article: determinants and assessment of cardiovascular risk in steatotic liver disease owing to metabolic dysfunction-addressing the challenge DOI Open Access
Mohamad Jamalinia, Amedeo Lonardo

Metabolism and Target Organ Damage, Journal Year: 2024, Volume and Issue: 4(3)

Published: June 26, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD) stands as an independent risk factor for cardiovascular (CVD), which is the leading cause of mortality among MASLD patients. The diverse spectrum cardio-nephro-metabolic and vascular manifestations inherent in highlights complex profile CVD associated with this condition. However, current approaches to assessing lack specificity, predominantly relying on traditional markers. Although it widely accepted that patients advanced fibrosis are more prone risk, recent evidence suggests isolated focus may overlook remarkable phenotypic variability across entire population. Emerging data indicate a progressive escalation parallel severity MASLD, highlighting need precise staging inform accurate assessment. To address challenge, we propose novel sequential approach assessment MASLD. While factors remain essential, incorporating liver-specific parameters enhances stratification guides targeted interventions mitigate substantial burden vulnerable This involves initial screening using FIB-4 NAFLD score, followed by imaging-based non-invasive techniques individuals at intermediate-high fat quantification low-risk individuals. Future prospective investigations should simultaneous use biomarkers imaging modalities evaluate, sex-specific manner, efficacy proposed determine optimal thresholds steatosis

Language: Английский

Citations

5